Emergent BioSolutions annual operating margin
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Emergent BioSolutions's operating margin was 13.47% for fiscal 2025.
View full Emergent BioSolutions company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 13.47% | +23.89 pp |
| 2024 | 2024-12-31 | −10.42% | +58.81 pp |
| 2023 | 2023-12-31 | −69.23% | −54.01 pp |
| 2022 | 2022-12-31 | −15.21% | −34.46 pp |
| 2021 | 2021-12-31 | 19.25% | −8.94 pp |
| 2020 | 2020-12-31 | 28.19% | +17.88 pp |
| 2019 | 2019-12-31 | 10.32% | −1.16 pp |
| 2018 | 2018-12-31 | 11.48% | −10.68 pp |
| 2017 | 2017-12-31 | 22.16% | +0.58 pp |
| 2016 | 2016-12-31 | 21.58% | −5.49 pp |
| 2015 | 2015-12-31 | 27.07% | +7.26 pp |
| 2014 | 2014-12-31 | 19.81% | +6.13 pp |
| 2013 | 2013-12-31 | 13.69% | +3.06 pp |
| 2012 | 2012-12-31 | 10.63% | −1.11 pp |
| 2011 | 2011-12-31 | 11.74% | −13.96 pp |
| 2010 | 2010-12-31 | 25.70% | +8.60 pp |
| 2009 | 2009-12-31 | 17.10% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −53.39% | −54.53 pp |
| Q1 2026 | 2026-03-31 | 6.73% | −15.73 pp |
| Q4 2025 | 2025-12-31 | −18.76% | −13.88 pp |
| Q3 2025 | 2025-09-30 | 33.10% | +11.15 pp |
| Q2 2025 | 2025-06-30 | 1.14% | +81.03 pp |
| Q1 2025 | 2025-03-31 | 22.46% | +9.21 pp |
| Q4 2024 | 2024-12-31 | −4.88% | +10.96 pp |
| Q3 2024 | 2024-09-30 | 21.95% | +111.45 pp |
| Q2 2024 | 2024-06-30 | −79.90% | +6.78 pp |
| Q1 2024 | 2024-03-31 | 13.25% | +103.08 pp |
| Q4 2023 | 2023-12-31 | −15.84% | +0.91 pp |
| Q3 2023 | 2023-09-30 | −89.50% | −70.62 pp |
| Q2 2023 | 2023-06-30 | −86.68% | −55.23 pp |
| Q1 2023 | 2023-03-31 | −89.84% | −92.10 pp |
| Q4 2022 | 2022-12-31 | −16.75% | −54.55 pp |
| Q3 2022 | 2022-09-30 | −18.88% | −8.34 pp |
| Q2 2022 | 2022-06-30 | −31.45% | −35.10 pp |
| Q1 2022 | 2022-03-31 | 2.26% | −25.55 pp |
| Q4 2021 | 2021-12-31 | 37.81% | −7.27 pp |
| Q3 2021 | 2021-09-30 | −10.55% | −26.46 pp |
| Q2 2021 | 2021-06-30 | 3.65% | −28.28 pp |
| Q1 2021 | 2021-03-31 | 27.81% | +33.84 pp |
| Q4 2020 | 2020-12-31 | 45.08% | +23.55 pp |
| Q3 2020 | 2020-09-30 | 15.91% | −6.76 pp |
| Q2 2020 | 2020-06-30 | 31.92% | +34.80 pp |
| Q1 2020 | 2020-03-31 | −6.03% | +8.24 pp |
| Q4 2019 | 2019-12-31 | 21.53% | +17.40 pp |
| Q3 2019 | 2019-09-30 | 22.67% | +10.41 pp |
| Q2 2019 | 2019-06-30 | −2.88% | −33.21 pp |
| Q1 2019 | 2019-03-31 | −14.27% | −6.21 pp |
| Q4 2018 | 2018-12-31 | 4.14% | −23.25 pp |
| Q3 2018 | 2018-09-30 | 12.27% | −19.70 pp |
| Q2 2018 | 2018-06-30 | 30.34% | +21.87 pp |
| Q1 2018 | 2018-03-31 | −8.06% | −20.82 pp |
| Q4 2017 | 2017-12-31 | 27.39% | −8.05 pp |
| Q3 2017 | 2017-09-30 | 31.97% | +7.14 pp |
| Q2 2017 | 2017-06-30 | 8.46% | +10.70 pp |
| Q1 2017 | 2017-03-31 | 12.76% | −6.30 pp |
| Q4 2016 | 2016-12-31 | 35.44% | −15.25 pp |
| Q3 2016 | 2016-09-30 | 24.82% | −13.47 pp |
| Q2 2016 | 2016-06-30 | −2.24% | −19.25 pp |
| Q1 2016 | 2016-03-31 | 19.06% | +63.55 pp |
| Q4 2015 | 2015-12-31 | 50.69% | −0.50 pp |
| Q3 2015 | 2015-09-30 | 38.29% | +15.80 pp |
| Q2 2015 | 2015-06-30 | 17.01% | +9.88 pp |
| Q1 2015 | 2015-03-31 | −44.49% | +2.76 pp |
| Q4 2014 | 2014-12-31 | 51.19% | +27.45 pp |
| Q3 2014 | 2014-09-30 | 22.49% | +2.13 pp |
| Q2 2014 | 2014-06-30 | 7.13% | −10.72 pp |
| Q1 2014 | 2014-03-31 | −47.25% | −16.27 pp |
| Q4 2013 | 2013-12-31 | 23.74% | −1.66 pp |
| Q3 2013 | 2013-09-30 | 20.37% | +5.62 pp |
| Q2 2013 | 2013-06-30 | 17.85% | +5.55 pp |
| Q1 2013 | 2013-03-31 | −30.97% | −6.05 pp |
| Q4 2012 | 2012-12-31 | 25.41% | −17.20 pp |
| Q3 2012 | 2012-09-30 | 14.74% | +12.35 pp |
| Q2 2012 | 2012-06-30 | 12.29% | −10.63 pp |
| Q1 2012 | 2012-03-31 | −24.92% | +166.66 pp |
| Q4 2011 | 2011-12-31 | 42.60% | +14.75 pp |
| Q3 2011 | 2011-09-30 | 2.40% | −21.44 pp |
| Q2 2011 | 2011-06-30 | 22.93% | — |
| Q1 2011 | 2011-03-31 | −191.58% | — |
| Q3 2010 | 2010-09-30 | 27.85% | — |
| Q2 2010 | 2010-06-30 | 23.84% | — |
Over the last five reported fiscal years, Emergent BioSolutions's operating margin decreased from 28.19% to 13.47%, a change of −14.72 percentage points. The latest reported quarter, Q2 2026, shows −53.39%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Emergent BioSolutions filings at SEC.gov ↗